Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
Clinical trial NCT06569524 · RECRUITING
Trial details
- NCT number
- NCT06569524
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-14
- Primary completion
- 2026-12-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.